

# PENDAL

## Pendal Australian Share Fund

ARSN: 089 935 964

## Factsheet

Equity Strategies

January 2020

### About the Fund

The Pendal Australian Share Fund (**Fund**) is an actively managed portfolio of Australian shares.

### Investment Return Objective

The Fund aims to provide a return (before fees, costs and taxes) that exceeds the S&P/ASX 300 (TR) Index over the medium to long term. The suggested investment timeframe is five years or more.

### Description of Fund

This Fund is designed for investors who want the potential for long term capital growth and tax effective income, diversification across a broad range of Australian companies and industries and are prepared to accept higher variability of returns. The Fund may also hold cash and may use derivatives.

Pendal's investment process for Australian shares is based on our core investment style and aims to add value through active stock selection and fundamental company research. Pendal's core investment style is to select stocks based on our assessment of their long term worth and ability to outperform the market, without being restricted by a growth or value bias. Our fundamental company research focuses on valuation, franchise, management quality and risk factors (both financial and non-financial risk).

Derivatives may be used to reduce risk and can act as a hedge against adverse movements in a particular market and/or in the underlying assets. Derivative can also be used to gain exposure to assets and markets.

### Investment Team

Pendal's nineteen member Equity team is one of the largest in the Australian fund's management industry. The portfolio manager for the Fund is Crispin Murray, who has more than 28 years' industry experience. Crispin is also Head of Equity.

### Investment Guidelines

Ex-ante (forward looking) tracking error	2.0% - 6.0%
Min/max stock position	+/-4%
Min/max sector position	+/-8%

### Other Information

Fund size (as at 31 Jan 2020)	\$1,017 million
Date of inception	September 1992
Minimum investment	\$25,000
Buy-sell spread <sup>1</sup>	0.50% (0.25%/0.25%)
Distribution frequency	Quarterly
APIR code	RFA0818AU

<sup>1</sup> The buy-sell spread represents transaction costs incurred whenever you invest or withdraw funds, and may vary from time to time without notice.

### Management Costs<sup>2</sup>

Issuer fee <sup>3</sup>	0.79% pa
-------------------------	----------

<sup>2</sup> You should refer to the latest Product Disclosure Statement for full details of fees and other costs you may be charged.

<sup>3</sup> This is the fee we charge for overseeing the operations of the Fund and managing the assets of the Fund. The Issuer fee is paid from the assets of the Fund and is reflected in the unit price of your investment.

### Performance

(%)	Total Returns		Benchmark Return
	(post-fee)	(pre-fee)	
1 month	4.10	4.17	4.89
3 months	6.60	6.82	6.03
FYTD	8.72	9.23	8.32
6 months	6.06	6.48	5.20
1 year (pa)	24.77	25.78	24.99
2 years (pa)	10.72	11.61	12.40
3 years (pa)	12.35	13.25	12.39
5 years (pa)	9.13	10.00	9.42

### Sector Allocation (as at 31 January 2020)

Energy	7.9%
Materials	18.8%
Industrials	11.2%
Consumer Discretionary	5.7%
Consumer Staples	2.5%
Health Care	12.3%
Information Technology	2.9%
Telecommunication Services	7.6%
Financials ex Property Trusts	25.1%
Property Trusts	4.4%
Cash & other	1.6%

### Top 10 Holdings (as at 31 January 2020)

CSL Limited	9.3%
Commonwealth Bank of Australia Ltd	6.7%
BHP Billiton Limited	6.1%
Telstra Corporation Limited	5.3%
ANZ Banking Group Limited	4.7%
Westpac Banking Corporation	4.0%
Qantas Airways Limited	3.5%
Santos Limited	3.4%
Macquarie Group Limited	3.3%
Transurban Group	3.1%

### Risks

An investment in the Fund involves risk, including:

- **Market risk:** The risk that factors affecting one or more countries that can influence the direction and volatility of an overall market, as opposed to security-specific risks.
- **Security specific risk:** The risks associated with an individual security.

Please read the Fund's Product Disclosure Statement (**PDS**) for a detailed explanation of each of these risks.

## Market review

The market staged a strong start to 2020, with the S&P/ASX 300 Accumulation index gaining +4.9% in January. However with Resources up only +0.65% and Financials (+4.7%) somewhat in-line with the market, the gains were concentrated in narrow part of the market – particularly Health Care (+12.0%), Information Technology (+10.2%) and Consumer Staples (+7.8%).

This rotation away from cyclicals - and towards bond-sensitive defensive and growth stocks – is a reversal of the prevailing theme of the last quarter and reflects a cautious turn in investor sentiment in recent weeks. Coronavirus has played a role in this, but even prior to this uncertainty there had been some weaker signals on global growth. Copper has fallen over 8% during the month and oil is down almost 20%, while gold is up 1%. People are now looking for further monetary easing to support the global economy, with a further 50bps of rate cuts currently priced into the bond market. US 10 year bond yields contracted 41bps to 1.51% over the month, while their Australian equivalents came in 42bps to 0.95%.

A few companies kicked off the year with a downgrade. Treasury Wine Estates (TWE, -20.0%) released its results early and shifted full year earnings growth expectations from 15-20% down to 5-10%. Management cited a squeeze on its bulk wine business in the US, which is seeing rising costs from Australian grapes, while stronger competition is limiting its ability to pass the costs on.

Health insurer NIB (NIB, -13.7%) downgraded full year operating profit by 15%. This reflects broader pressure on the health insurance industry structure. More younger people are opting out of private health insurance, or trading down, as the requirement to cross-subsidise older holders is leading to higher premiums. At the same time, claims inflation remains strong.

Insurance Australia Group (IAG, -7.6%) also downgraded its expected insurance margins to 14.5-16.5% versus previous guidance of 16-18%. This followed a review of natural perils claims, prompted by a 2019 hailstorm. Underlying operations remain decent and the industry structure remains supportive in terms of its ability to price risk. A one off remediation charge also exacerbated the downgrade.

Elsewhere the combination of bushfires and the coronavirus – and the potential effects on travel and tourism - hit a raft of stocks including Flight Centre (FLT, -10.8%), Qantas (QAN, -9.9%), Star Entertainment (SGR, -9.1%) and Sydney Airport (SYD, -3.1%). The underperformance of global cyclicals such as BlueScope Steel (BSL, -5.4%) and Alumina (AWC, -5.2%) indicates the broader uncertainties over the global economy.

The list of better performing stocks looks like carbon copy of 1H 2019 and reflects the more negative bent in sentiment and lower bond yields. Afterpay Touch (APT) was up 31.7%, while fellow technology stocks Altium (ALU, +14.7%), Appen (APX, +12.9%), Wisetech (WTC, 7.1%) and Xero (XRO, +7.0%) also outperformed.

Health care, the other key growth sector, was also strong. ResMed (RMD) was up +14.4% and CSL (CSL) +13.2%. The latter continues to benefit from a shortage in plasma supply in the US. More efficient use of blood in surgery has meant that the Red Cross, which supplies 25% of the market, has not been growing collections. Meanwhile demand for immunoglobulin (IG) products sourced from blood plasma has been growing in the mid to high single digits each year. CSL has benefited from the twin tailwinds of higher US prices, as well as a mix shift as it supplies more product into the US.

## Fund performance

The Fund underperformed its benchmark over the month of January.

## Contributors

### Do not hold Treasury Wine Estates

Treasury Wine Estates (TWE, -20.0%) released its results early and shifted full year earnings growth expectations from 15-20% down to 5-10%. Management cited a squeeze on its bulk wine business in the US, which is seeing rising costs from Australian grapes, while stronger competition is limiting its ability to pass the costs on. In our view the US business faces broader issues, with a revamped distribution model not delivering gains in market share, while management changes have proved a distraction.

## Overweight CSL

CSL (+13.2%) continues to benefit from a shortage in plasma supply in the US. More efficient use of blood in surgery has meant that the Red Cross, which supplies 25% of the market, has not been growing collections. Meanwhile demand for immunoglobulin (IG) products sourced from blood plasma has been growing in the mid to high single digits each year. CSL has benefited from the twin tailwinds of higher US prices, as well as a mix shift as it supplies more product into the US.

## Detractors

### Overweight Qantas

Our high conviction position Qantas (QAN, -9.8%) pulled back over the month, and weighed on relative performance. The combination of bushfires and the coronavirus – and the potential effects on travel and tourism - hit a raft of stocks including Qantas.

### Do not hold Woolworths

Consumer staples such as Woolworths (WOW, +15.7%) and Coles (COL, +11.5%) benefited from a more defensive investor mindset. We believe that valuations in both look stretched, given low single digit earnings growth. Our preference remains for Metcash (MTS, +2.0%), which is valued at a historically wide discount to WOW and which has greater leverage to the shift in grocery price inflation.

## Strategy and outlook

The coronavirus has quickly replaced trade at the nexus of uncertainty over the outlook for Chinese economic growth. The rate at which infection rates are developing - and whether it is slowing – is a key factor in trying to gauge the length and scale of the ultimate impact from coronavirus. Nearer term, the focus will be on how China returns to work following the extended Lunar new year holiday. We will be keeping a close watch on this over the coming weeks.

Within China manufacturing may start to ramp up faster than construction, as the latter relies more on migrant labour which may be impacted by travel restrictions. The market is working through the implications for commodity demand. There are also questions over the impact on regional and global supply chains, with stories emerging of some auto plants experience issues as they run short of components.

This issue is likely to have implications of some degree for a swathe of Australian industries and companies. The effect on commodity demand is front and centre for the resource sector - and extends beyond the first order implications for iron ore demand. For example, CNOOC, China's largest buyer of LNG, has declared force majeure and stated that it is unable to take delivery of some contracted LNG shipments due to the impact of coronavirus. This could ultimately lead to gas originally intended for export finding its way into the Australian domestic east coast market, putting pressure on prices and on domestic gas suppliers.

There are also likely to be impacts on companies which sell to Chinese consumers. Treasury Wine Estate, for example, downgraded in January on a weaker outlook for the US business - however the effects of any hit to demand in China or disruption in distribution are still yet to feed through.

As always, there will be industries, companies and management teams who are better placed to deal with these issues than others. Some industries will be able to make adjustments. Airlines such as Qantas, for example, have the ability to react to weaker demand for flights via reduced capacity. For the miners, in contrast, mined ore not bought by Chinese steel plants sits as unsold inventory.

The outlook for China is just one factor the market must think through as we enter reporting season. Across the Pacific, data from the US provided a brighter counterpoint to concerns over China as monthly employment came in much stronger than expected. We believe that the US economy remains in reasonable shape. This is important because the effects of any Chinese demand shock will take place against a US economy which has some momentum, rather than one hovering at stall speed.

The domestic economy remains patchy, however we are mindful that any signs of an improvement – perhaps in response to government stimulus – may see a sharp rebound in lowly-rated cyclicals. This rebound may be enhanced by the degree of valuation dispersion between cyclicals and growth stocks.

For more information please call **1800 813 886**,  
contact your key account manager or visit [pendalgroup.com](http://pendalgroup.com)

**PENDAL**

This factsheet has been prepared by Pental Fund Services Limited (**PFSL**) ABN 13 161 249 332, AFSL No 431426 and the information contained within is current as at the date of this factsheet. It is not to be published, or otherwise made available to any person other than the party to whom it is provided.

PFSL is the responsible entity and issuer of units in the Pental Australian Share Fund (**Fund**) ARSN: 089 935 964. A product disclosure statement (**PDS**) is available for the Fund and can be obtained by calling 1800 813 886 or visiting [www.pentalgroup.com](http://www.pentalgroup.com). You should obtain and consider the PDS before deciding whether to acquire, continue to hold or dispose of units in the Fund. An investment in the Fund is subject to investment risk, including possible delays in repayment of withdrawal proceeds and loss of income and principal invested.

This factsheet is for general information purposes only, should not be considered as a comprehensive statement on any matter and should not be relied upon as such. It has been prepared without taking into account any recipient's personal objectives, financial situation or needs. Because of this, recipients should, before acting on this information, consider its appropriateness having regard to their individual objectives, financial situation and needs. This information is not to be regarded as a securities recommendation.

The information in this factsheet may contain material provided by third parties, is given in good faith and has been derived from sources believed to be accurate as at its issue date. While such material is published with necessary permission, and while all reasonable care has been taken to ensure that the information in this factsheet is complete and correct, to the maximum extent permitted by law neither PFSL nor any company in the Pental group accepts any responsibility or liability for the accuracy or completeness of this information.

Performance figures are calculated in accordance with the Financial Services Council (**FSC**) standards. Where performance returns are quoted "Post fees" then this assumes reinvestment of distributions and is calculated using exit prices which take into account management costs but not tax you may pay as an investor. Where performance returns are quoted "Pre fees and tax", they exclude the effects of management costs and any taxes. Past performance is not a reliable indicator of future performance.

If market movements, cash flows or changes in the nature of an investment (e.g. a change in credit rating) cause the Fund to exceed any of the investment ranges or limits specified, this will be rectified by PFSL as soon as reasonably practicable after becoming aware of it. If PFSL does so, it will have no other obligations in relation to these circumstances. The procedures, investment ranges, benchmarks and limits specified are accurate as at the date of this factsheet and PFSL reserves the right to vary these from time to time.